If you use 7-OH and you’ve been following the news lately, you may be wondering whether the federal government has finally banned it.
As of August 26, 2026, the answer is no—not yet.
The DEA has now placed three potent kratom-related compounds into Schedule I: mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16.
But the separate federal action targeting concentrated 7-hydroxymitragynine, or 7-OH, is still in progress. In fact, federal officials just extended the public-comment period surrounding the proposed 7-OH threshold through September 10.
That distinction matters because several federal actions are happening around kratom-derived products at the same time, and it’s becoming very easy to read a headline and walk away thinking:
“The DEA just banned kratom.”
That’s not what happened.
And if you’re currently using 7-OH, I think it’s worth understanding what did happen—not just because of the legal details, but because the market around these products may be about to change considerably.
What Did the DEA Just Put Into Schedule I?
On August 25, the Department of Justice announced the emergency scheduling of three compounds:
- Mitragynine pseudoindoxyl (MGPI)
- MGM-15
- MGM-16
The temporary scheduling order takes effect upon publication in the Federal Register on August 26.
These aren’t simply other names for ordinary kratom powder.
They’re potent opioid compounds chemically related to mitragynine or 7-OH. According to the Justice Department, MGPI and MGM-15 have already been manufactured and marketed in consumer products for their opioid effects. MGM-16 has not been confirmed in the consumer market, but federal officials are acting before it potentially emerges as an alternative to related compounds.
This is an important change from where things stood earlier this summer.
In July, DEA announced that it intended to temporarily schedule these compounds.
Now it’s actually happening.
Once the order takes effect, MGPI, MGM-15, and MGM-16 become subject to the federal controls that apply to Schedule I controlled substances.
But there’s one thing I want to make especially clear:
This is not the same federal action as the proposed scheduling of concentrated 7-OH.
So, Is 7-OH Banned Federally?
Not under the separate 7-OH scheduling action—not yet.
This is where things get confusing.
Back in July, DEA announced its intent to temporarily place 7-OH above a specified threshold into Schedule I.
The key phrase is above a specified threshold.
DEA didn’t propose simply putting every detectable amount of 7-OH into Schedule I. Its proposed framework distinguishes elevated or concentrated 7-OH products from the trace amounts that can occur in botanical kratom.
And on August 26, there was another important development.
The Office of the Assistant Secretary for Health extended the public-comment period concerning that proposed threshold until September 10, 2026.
The notice is fairly narrow. It’s asking for input concerning the threshold used for temporary scheduling. It isn’t reopening the entire question of kratom, deciding whether kratom products are generally useful or safe, or making a permanent scheduling decision.
So as I write this, the easiest way to understand the situation is:
MGPI, MGM-15, and MGM-16: being placed into Schedule I now.
Concentrated 7-OH above DEA’s proposed threshold: still going through a separate temporary-scheduling process.
Traditional botanical kratom below the proposed threshold: not included in that proposed 7-OH scheduling action.
Those are three different things.
And right now, they’re getting blurred together constantly.
I’ve been where you are. Let me help.
I’ve been through this myself. These are the emails I wish I had when I was trying to quit — things that helped me through the hard days, lessons I learned the hard way, and what finally helped me get free and stop going back.
No spam. Just real emails from someone who’s been there.
Is Kratom Itself Being Federally Banned?
No.
And this isn’t just a technical interpretation of what federal officials are doing.
The Justice Department explicitly says its latest scheduling action is directed at deliberately manufactured and concentrated opioid products, not traditional botanical kratom.
There’s even an interesting wrinkle involving MGPI.
Federal officials say there are unresolved scientific and analytical questions about whether incidental trace amounts of MGPI can sometimes appear in otherwise botanical kratom because of processing, storage, or analytical conditions.
Because of that uncertainty, DOJ says it intends to exercise enforcement discretion when only incidental trace MGPI is confirmed in a product otherwise consistent with botanical kratom.
That discretion does not extend to intentionally added, manufactured, concentrated, or fortified MGPI. And it doesn’t apply to MGM-15 or MGM-16.
The broader distinction is becoming increasingly difficult to miss:
Federal regulators are not currently treating traditional botanical kratom and manufactured high-potency kratom-derived opioids as the same thing.
That doesn’t mean the regulatory future of botanical kratom is settled forever.
It means that when someone says “DEA just scheduled kratom,” they’re leaving out an enormous part of the story.
What About the 7-OH Products People Are Actually Buying?
This is probably the more important question if you’re reading this because you actually use 7-OH.
The commercial 7-OH market looks very different from traditional kratom leaf.
High-potency 7-OH is now sold in products like tablets, capsules, powders, gummies, and dissolvable strips. These products can contain substantially more 7-OH than you would naturally encounter in botanical kratom.
That’s the market federal regulators are targeting.
Under DEA’s proposed framework, botanical material containing more than 0.050% 7-OH by dry weight would cross the proposed threshold.
For certain other products, the framework also uses concentration and per-article limits, including a 1 mg per article threshold in specified circumstances.
Those details aren’t particularly exciting unless you’re a regulator or manufacturer.
What matters to someone actually using these products is simpler:
The federal government is clearly moving toward removing high-potency 7-OH and related manufactured opioids from ordinary consumer retail.
The exact 7-OH threshold is still being worked through.
The direction of travel isn’t nearly as ambiguous.
If You Use 7-OH, This May Matter More Than the Legal Terminology
I understand why people want to know exactly when something becomes illegal.
If you’ve become dependent on a product, whether you’ll still be able to buy it next month is a pretty important question.
But if you’ve already been thinking about getting off 7-OH, there’s another question worth asking:
Do you actually want to keep depending on it?
Maybe you’ve reached the point where you’re constantly thinking about your next dose.
Maybe what started as something useful doesn’t feel very useful anymore.
Maybe you’ve tried stopping and discovered that getting through a day without it is much harder than you expected.
Maybe you’re spending more than you ever intended.
Or maybe you’re simply tired of having part of your life organized around whether you have enough of this stuff available.
If that’s where you are, the regulatory situation might be what brought you to this article.
But regulation isn’t necessarily the most important reason to make a change.
You don’t need to wait for the DEA to make the decision for you.
Don’t Make Availability Your Recovery Plan
One response we’re probably going to see if concentrated 7-OH becomes harder to find is people switching back to ordinary kratom powder.
I understand the logic.
If one product disappears, switching to something that’s still available can feel like the obvious solution.
And depending on someone’s situation, what they do next is ultimately their decision.
But if what you actually want is freedom from having to rely on kratom at all, substitution doesn’t necessarily solve that problem.
It may change the product.
It doesn’t automatically change the relationship you have with it.
That’s the part I think gets overlooked when we talk about quitting.
Getting through withdrawal matters. Getting those first days behind you matters.
But eventually, there’s another problem waiting:
How do I live without feeling like I need this anymore?
Because if kratom still feels like the thing that makes life manageable—something you need for energy, stress, boredom, work, anxiety, sleep, motivation, or simply feeling okay—then staying away from it can turn into a constant argument with yourself.
That’s exhausting.
And it’s why I don’t think recovery ends when the substance leaves your body.
The deeper work is learning how to live without continually needing a substance to change how life feels.
If the Crackdown Is Making You Think About Quitting 7-OH
Then I’d use that.
Not the panic around it. Not rumors about exactly when stores will run out.
Just the clarity it might be giving you.
Maybe you don’t want to keep doing this.
Start there.
Get clear about why you want out.
Pay attention to what 7-OH is actually doing for you today versus what you still believe it’s doing for you.
Notice the situations where your brain immediately reaches for the same answer:
I need 7-OH.
Stress.
Exhaustion.
Work.
Boredom.
Feeling low.
Wanting relief.
Wanting to feel different for a while.
Those connections matter because simply removing the substance doesn’t automatically remove everything you learned to associate with it.
That’s why I think recovery has to go further than:
Just don’t use today.
Of course staying off matters.
But I don’t want to spend my life desperately wanting something and congratulating myself for successfully resisting it.
I want freedom.
And to me, that means eventually reaching a place where kratom doesn’t feel necessary, valuable, or like the answer to whatever life happens to throw at me.
Whether 7-OH disappears next month, gets reformulated, becomes harder to find, or remains available longer than expected doesn’t change that goal.
So Where Do Things Stand Right Now?
As of August 26, 2026, here’s the simplest way I can put it:
Traditional kratom leaf has not been federally placed into Schedule I by these actions.
MGPI, MGM-15, and MGM-16 are being placed into Schedule I.
Concentrated 7-OH above a specified threshold remains the subject of a separate temporary-scheduling process, and the comment period concerning that threshold has now been extended through September 10.
So no, saying “DEA banned kratom” isn’t accurate.
And saying the separate proposed 7-OH scheduling action has already taken effect isn’t accurate either.
But if you’re using high-potency 7-OH, I also wouldn’t ignore what’s happening.
Federal regulators are moving aggressively against this category of products.
And if you’ve already reached the point where you know you want out, you don’t need to wait around to see exactly how the regulatory story ends.
You can start working toward being free now.
Frequently Asked Questions
Is 7-OH banned federally?
As of August 26, 2026, the separate DEA temporary-scheduling process for 7-OH above a specified threshold has not yet resulted in the temporary scheduling order described in the July notice of intent. The federal comment period concerning the proposed threshold has been extended through September 10, 2026.
Did the DEA ban kratom?
No. The latest federal action places MGPI, MGM-15, and MGM-16 into Schedule I. DOJ specifically distinguishes the manufactured and concentrated opioid products targeted by the action from traditional botanical kratom.
What did the DEA just put into Schedule I?
DEA’s August 2026 temporary scheduling action covers mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16, along with the forms specified in the federal order.
Is traditional kratom leaf Schedule I?
No. Traditional botanical kratom has not been federally placed into Schedule I by these 2026 actions.
Could 7-OH still become Schedule I?
Yes. DEA has announced its intent to temporarily schedule 7-OH above a specified threshold. The threshold remains part of an ongoing federal process, with the HHS/OASH comment period now extended through September 10, 2026.
Sources
- U.S. Department of Justice — “Justice Department Announces Emergency Scheduling of Three Potent Opioid Compounds,” August 25, 2026
https://www.justice.gov/opa/pr/justice-department-announces-emergency-scheduling-three-potent-opioid-compounds - Federal Register — “Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I,” August 26, 2026
https://www.federalregister.gov/ - Federal Register — “7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Extension of Comment Period,” August 26, 2026
https://www.federalregister.gov/documents/2026/08/26/2026-17409/hydroxymitragynine-above-a-specified-threshold-in-schedule-i-extension-of-comment-period - Federal Register — “Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I,” July 6, 2026
https://www.federalregister.gov/documents/2026/07/06/2026-13580/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-above-a-specified - Federal Register — “Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I,” July 6, 2026
https://www.federalregister.gov/documents/2026/07/06/2026-13581/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and
Alex Stone
Writes about kratom and 7-OH for K-Free.
